Rock Springs Capital SGMT Position
ExitedRock Springs Capital exited their position in Sagimet Biosciences Inc. (SGMT) in Q2 2025, after holding the stock for 8 quarters.
The position was first reported in Q3 2023 and has been tracked across 8 quarterly 13F filings.
2 other tracked funds also hold SGMT.
Short interest stands at 12.8% of float with 9.9 days to cover, indicating significant bearish positioning against the stock.
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Full company profile →Short Interest
12.8%
9.9 days to cover
Rock Springs Capital SGMT Position History
Frequently Asked Questions
Does Rock Springs Capital own SGMT?
No. Rock Springs Capital exited their position in Sagimet Biosciences Inc. (SGMT) in Q2 2025. They previously held the stock for 8 quarters.
How many hedge funds own SGMT?
2 specialist biotech hedge funds currently hold SGMT, including Baker Bros. Advisors, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy SGMT?
Rock Springs Capital's position in SGMT was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's SGMT position increasing or decreasing?
Rock Springs Capital completely exited their SGMT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SGMTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →